Concordia International (CXR) Stock Price, News & Analysis

Company Overview

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$25.04 to C$25.04
• 52-Week Range: N/A
• Volume: 73,541 shs
• Average Volume: 4,054 shs
• Market Capitalization: C$1.22 billion
• P/E Ratio: 0.07
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CXR Stock Analysis - Frequently Asked Questions

How do I buy shares of Concordia International?

Shares of CXR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Concordia International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Concordia International investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy (VET) and Wheaton Precious Metals (WPM).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Transportation
• Current Symbol: TSE:CXR
• CUSIP: N/A
• CIK: N/A
• Web: concordiarx.com
• Phone: +1-905-8425150
• Fax: N/A
• Employees: 22,500
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.07
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 457.02
• Current Ratio: 2.10
• Quick Ratio: 1.66

Sales & Book Value

• Annual Sales: C$569.62 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 5.85
• Book Value: C$6.08 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 48,913,000
• Free Float: N/A
• Market Cap: C$1.22 billion
• Optionable: Not Optionable
• Beta: N/A